StocksFin Logo
Amicus Therapeutics, Inc. country of incorporation
|
|
Mr. John Crowley
|
496 employees
NASDAQ | Healthcare | Biotechnology
NASDAQ | Healthcare | Healthcare Plans
Q322 reported Nov 7, 2022 Reporting Period
$81.69M 2.7% vs. Q321 Revenues Q322
83.55% -2% vs. Q321 Gross Profit Margin
-40.75% ! 35.6% vs. Q321 Net Profit Margin
-11.49M ! 51.5% vs. Q321 Free Cash Flow Q322
$-0.12 ! 36.8% vs. Q321 EPS Q322
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Q322 reported Nov 3, 2022 Reporting Period
$360.35M 22.8% vs. Q321 Revenues Q322
13.18% -2% vs. Q321 Gross Profit Margin
-11.17% ! 28.5% vs. Q321 Net Profit Margin
98.57M 663.3% vs. Q321 Free Cash Flow Q322
$-0.22 ! 15.4% vs. Q321 EPS Q322
-
Period
Profitable?
Revenue Growth?
Net Profit Growth?
FCF Growth?
OCF Growth?
EPS Growth?
Pays Dividend?
Q322
Q322
Loading...
Loading...
Ratios
As of
Sep 30, 2022
Sep 30, 2022
Quick Ratio
2.47
1.93
Current Ratio
2.78
2.03
Cash Ratio
1.69
1.67
Price to Book
22.78
7.92
Price to Sales
36.96
5.98
Price to Earnings
-22.68
-13.39